Immunovant Inc
NASDAQ:IMVT
Immunovant Inc
NASDAQ:IMVT
Price:
25.17 USD
-1.02%
Market Closed
Updated:
Jun 10, 2024
Immunovant Inc
Total Liabilities
|
Immunovant Inc
Total Liabilities Peer Comparison
Comparables:
ABBV
GILD
AMGN
VRTX
REGN
Competitive Total Liabilities Analysis
Latest Figures & CAGR of Competitors
Latest Figures & CAGR of Competitors
| Company | Total Liabilities | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
|
Immunovant Inc
NASDAQ:IMVT
|
Total Liabilities
$48.6m
|
CAGR 3-Years
32%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Abbvie Inc
NYSE:ABBV
|
Total Liabilities
$140.9B
|
CAGR 3-Years
1%
|
CAGR 5-Years
17%
|
CAGR 10-Years
19%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Total Liabilities
$38.8B
|
CAGR 3-Years
-7%
|
CAGR 5-Years
-1%
|
CAGR 10-Years
10%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Total Liabilities
$88B
|
CAGR 3-Years
18%
|
CAGR 5-Years
11%
|
CAGR 10-Years
7%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Total Liabilities
$5.4B
|
CAGR 3-Years
20%
|
CAGR 5-Years
24%
|
CAGR 10-Years
19%
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Total Liabilities
$7.4B
|
CAGR 3-Years
8%
|
CAGR 5-Years
17%
|
CAGR 10-Years
22%
|
See Also
What is Immunovant Inc's Total Liabilities?
Total Liabilities
48.6m
USD
48.6m
USD
Based on the financial report for Mar 31, 2024, Immunovant Inc's Total Liabilities amounts to 48.6m USD.
What is Immunovant Inc's Total Liabilities growth rate?
Total Liabilities CAGR 3Y
32%
32%
Over the last year, the Total Liabilities growth was 12%. The average annual Total Liabilities growth rates for Immunovant Inc have been 32% over the past three years .
You don't have any saved screeners yet
